Omrix Completes Enrollment Of Initial 90 Patients Needed To Conduct Interim Analysis In Fibrin Pad U.S. Phase II Clinical Trial Omrix Biopharmaceuticals, Inc. ("Omrix") (NASDAQ: OMRI), a fully-integrated biopharmaceutical company that develops and markets biosurgical and immunotherapy products, announced today that it has completed enrollment of the first 90 patients in its Phase II clinical trial for the Fibrin Pad in mild to moderate bleeding.
Source: www.medicalnewstoday.com1st 'Bernhard Dräger Award For Advanced Treatment Of Acute Respiratory Failure' Awarded To Dr Hermann Heinze The European Society for Intensive Care
Medicine (ESICM) has awarded the first 'Bernhard Dräger Award for Advanced Treatment of Acute Respiratory Failure' to Dr Hermann Heinze, from the Clinic for Anesthesiology and Intensive Care
Medicine at the Schleswig-Holstein University Hospital. The research prize, which is worth 15,000 Euros and was donated by Dräger, was presented during the Society's annual conference. Prof Dr V.
Source: www.medicalnewstoday.comWorld Food Programme To Phase Out Aid In Uganda, Including HIV/AIDS Support The United Nations World Food Programme will phase out food aid and HIV/AIDS support to Uganda, a United Nations official said on Thursday, Xinhua/ChinaView.cn.com reports. The plan could affect more than 1.5 million people.
Source: www.medicalnewstoday.comRuling Denying Antiabortion Group's Request To Circumvent Election Rules Should Be Upheld, Editorial Says A federal appeals court should support a ruling by a federal judge in Virginia that upheld federal regulations that limit spending on independent "underhanded attack ads," a New York Times editorial says (New York Times, 9/21). U.S. District Judge James Spencer in Richmond, Va.
Source: www.medicalnewstoday.comAcute Post-Operative Pain - Javelin Enrolls First Patient In An Open Label Safety Study Of Dyloject Javelin Pharmaceuticals, Inc. (Amex: JAV), a leading developer of novel products for pain management, today announced that it had enrolled the first patient in a planned Phase 3, single-arm, open label observational safety study for its injectable NSAID, Dyloject™ (diclofenac sodium).
Source: www.medicalnewstoday.comSinusitis Patients Suffer Pain Similar To Patients With Arthritis, Depression Although muscle and joint aches are common complaints for patients who suffer with chronic sinusitis, the seriousness of these issues is now better appreciated.
Source: www.medicalnewstoday.comUNAIDS Examines Challenges In China's Response To HIV/AIDS "Focus on China's AIDS Response," UNAIDS: Although China's HIV prevalence is less than 0.1% of the population, the country continues to experience challenges in addressing the virus, according to a report from UNAIDS.
Source: www.medicalnewstoday.comClearwater's Canadian At-Home Dizziness Treatment Device Cleared By FDA The U.S. Food and Drug Administration has cleared DizzyFIX, an at-home treatment for vertigo and dizziness which helps guide patients through the Epley maneuver, for sale in the U.S. "DizzyFIX will now be available by
prescription in the U.S. and is already available over-the-counter in Canada and other countries," said Dr. Alp Sener, MD, PhD.
Source: www.medicalnewstoday.comNoted Medical Physicist To Document OSLD Superiority At 50th ASTRO Annual Meeting Landauer, Inc. (NYSE: LDR), a recognized leader in personal and environmental radiation monitoring, announced that noted medical physicist, Paul A. Jursinic, Ph.D., will be presenting at ASTRO his findings on the superiority of Landauer's Optically Stimulated Luminescence Dosimetry (OSLD) for clinical dosimetric measurements. Dr.
Source: www.medicalnewstoday.com
# posted by Network @ 5:00 PM
